CITALOPRAM HYDROBROMIDE | A201450 | HETERO LABS LTD UNIT III
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Kaylin Bower FDA-2025-P-5493 · 4 docket documents Kaylin Bower filed this citizen petition requesting that the FDA Commissioner explain why the agency stated that the Patient Global Impression of Change (PGIC) is not a well-defined and reliable measure of endometriosis-associated pain, yet permitted its use as an instrument in Phase 3 trials and as | Other | 2025-10-20 | Open | Kaylin Bower |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1747
per ml
Lowest NADAC/Unit
$0.1747
per ml
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 31722056424CITALOPRAM HBR 10 MG/5 ML SOLN | $0.1747 | ML | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.